Advertisement

Picture Berlin Partner Hotspot for Startups 650x80px
Document › Details

Galapagos N.V.. (12/21/18). "Press Release: Galapagos to Present at 37th Annual J.P. Morgan Healthcare Conference". Mechelen.

Region Region San Francisco, CA
  Country United States (USA)
Organisations Organisation Galapagos N.V. (Euronext + Nasdaq: GLPG)
  Group Galapagos (Group)
  Organisation 2 J.P. Morgan Securities LLC
  Group JPMorgan Chase (Group)
Products Product J.P. Morgan 37th Annual Healthcare Conference 2019 San Francisco
  Product 2 drug discovery services
Index term Index term Galapagos–JPMorgan Chase: investor conference, 201901 supply service Galapagos presents at JP Morgan Healthcare Conference 2019
Persons Person van de Stolpe, Onno (Galapagos 1999– CEO + Founder before IntroGene BV + Molecular Probes Europe BV)
  Person 2 Goodwin, Elizabeth (Galapagos 201112 Director Investor Relations)
     


Galapagos NV (Euronext & NASDAQ: GLPG) will participate in the 37th Annual J.P. Morgan Healthcare Conference on January 8 & 9, 2019.

Onno van de Stolpe, CEO, will present on Wednesday, January 9 at 20:30 CET (11:30 a.m. Pacific time). The presentation will be live audio webcast and can be accessed via the following link: https://jpmorgan.metameetings.net/events/healthcare19/sessions/23994-galapagos-nv/webcast. A replay of the webcast will be available for 90 days on the Galapagos' website at www.glpg.com.


About Galapagos

Galapagos (Euronext & NASDAQ: GLPG) discovers and develops small molecule medicines with novel modes of action, three of which show promising patient results and are currently in late-stage development in multiple diseases. Our pipeline comprises Phase 3 through to discovery programs in inflammation, fibrosis, osteoarthritis and other indications. Our ambition is to become a leading global biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines. More information at glpg www.glpg.com.


Investors:

Elizabeth Goodwin
VP IR & Corporate Communications
+1 781 460 1784

Sofie Van Gijsel
Director IR
+32 485 19 14 15
ir@glpg.com

Media:

Evelyn Fox
Director Communications
+31 6 53 591 999
communications@glpg.com


Forward-looking statements

This release may contain forward-looking statements. Such forward-looking statements are not guarantees of future results. These forward-looking statements speak only as of the date of publication of this document. Galapagos expressly disclaims any obligation to update any forward-looking statements in this document, unless specifically required by law or regulation.

   
Record changed: 2019-01-06

Advertisement

Picture EBD Group Connector Personal Networking in Life Sciences 650x80

More documents for Galapagos (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture EBD Group ChinaBio Partnerting Forum 2021 651x80




» top